FDA Internal Review To Evaluate Potential Symlin Dosing Confusion

Agency evaluation follows a medication safety alert for the adjunctive diabetes therapy issued by the Institute for Safe Medication Practices. Watchdog group cites confusion in dosage instructions that could result in overdose/underdose of Symlin.

More from Archive

More from Pink Sheet